Liraglutide (Victoza 1 ) is a once-daily glucagon-like peptide-1 (GLP-1) mimetic currently prescribed as a therapy for type-2 diabetes (1) . Liraglutide mimics all of the glucoregulatory, insulin-releasing and extra-pancreatic actions of GLP-1, especially the glucose-dependent stimulation of insulin secretion (2) . Recent studies have shown that Liraglutide crosses the blood-brain-barrier when administered peripherally (3) and GLP-1R deficient mice exhibit impaired memory and learning (4) . Therefore, the present study examined the effects of daily treatment with Liraglutide on the cognitive function in an animal model of diet-induced obesity which exhibits compromised cognitive performance.
